In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Elizabeth A MendesDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0003-1296-7879 Aanandi MunshiDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0001-6899-4038 Archana SinghNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich, United Kingdom.ORCID 0000-0002-5027-4582 Maisie D EvansNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich, United Kingdom.ORCID 0000-0002-9064-8120 Hsien-Chao ChouOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID 0000-0002-4870-9663 Yong Yean KimOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID 0000-0002-5417-9232 Young SongOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Ara JoDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0003-0673-2053 Daniel LeeDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.ORCID 0009-0008-0478-6473 Jaida CiampiDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.ORCID 0009-0000-8146-5739 Audrey ChambersDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.ORCID 0009-0006-4327-6201 Samantha WeitzelDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.ORCID 0009-0001-0372-8406 Michael DeelDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-8634-8109 Javed KhanOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Darrell GreenNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich, United Kingdom.ORCID 0000-0002-0217-3322 Corinne M LinardicDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-3257-2885 Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8MScreening for Cys-Reactive Ligands to Target PAX3-FOXO1U54CA231630 · NCI · DUKE UNIVERSITY · PI LINARDIC, CORINNE MARY · 2019 to 2023
$6.5MCooperative Human Tissue Network Support through Duke's BioRepository & Precision Pathology CenterUM1CA239755 · NCI · DUKE UNIVERSITY · PI Shannon Jones McCall · 2019 to 2026
$5.4MCell and Molecular Biology Training ProgramT32GM142605 · NIGMS · DUKE UNIVERSITY · PI MICHAEL S BOYCE, Stefano Di Talia · 2021 to 2026
$3.7MNCI NIH HHS P30 CA014236NCI NIH HHS U54 CA231630NCI NIH HHS UM1 CA239755NIGMS NIH HHS T32 GM142605
6 · The paper itselfAbstract
Fusion-positive rhabdomyosarcoma is an aggressive pediatric cancer of skeletal muscle lineage, with a 5-year overall survival of <30% for high-risk disease, and <8% when metastatic. The
Indexed as
CADD522PAX3::FOXO1RhabdomyosarcomaRMSRUNX2
Identifiers
PMID40777370
PMCPMC12330556
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390